急性髓系白血病患者ASXL2和ZBTB7A基因突变及其与临床特征及预后的关系

Mutations of ASXL2 and ZBTB7A Genes in Patients with Acute Myeloid Leukemia and Their Relationship with Clinical Features and Prognosis

目的探究急性髓系白血病(AML)患者ASXL2和ZBTB7A基因突变及其与临床特征和预后的关系。方法选取急性髓系白血病患者84例,测序分析ASXL2和ZBTB7A基因突变情况,分析其与患者临床特征以及预后的关系。结果84例AML患者中27例(32.14%)发生ASXL2突变,8例(9.52%)发生ZBTB7A突变。ASXL2和ZBTB7A突变和野生型患者在年龄、性别或其他并发症方面差异均无统计学意义(P>0.05)。ASXL2突变患者的白细胞数量显著高于野生型患者(P<0.05),其他方面均无统计学差异(P>0.05)。AML患者ASXL2和ZBTB7A突变的CR率比较,差异无统计学意义(P>0.05)。ASXL2野生型患者的OS率、EFS率均显著高于突变型(P<0.05);ZBTB7A突变与OS率无相关性(P>0.05);ZBTB7A野生型患者的EFS率显著高于突变型(P<0.05)。结论急性髓系白血病ASXL2和ZBTB7A突变型患者的预后较差,ASXL2和ZBTB7A突变有可能成为预后不良的分子标志物。

Objective To explore the ASXL2 and ZBTB7A gene mutations and their relationship with clinical features and prognosis in patients with acute myeloid leukemia(AML).Methods A total of 84 patients with acute myeloid leukemia were selected,and the ASXL2 and ZBTB7A gene mutations were sequenced and analyzed,and their relationship with the clinical characteristics and prognosis of the patients was analyzed.Results Among the 84 AML patients,27(32.14%)had ASXL2 mutation,and 8(9.52%)had ZBTB7A mutation.There was no significant difference in age,gender or other complications between ASXL2 and ZBTB7A mutant and wild-type patients(P>0.05).The number of leukocytes in ASXL2 mutant patients was significantly higher than that in wild-type patients(P<0.05),and there was no statistical difference in other aspects(P>0.05).There was no significant difference in the CR rates of ASXL2 and ZBTB7A mutations in AML patients(P>0.05).The OS rate and EFS rate of ASXL2 wild-type patients were significantly higher than those of mutant type(P<0.05),ZBTB7A mutation had no correlation with OS rate(P>0.05);the EFS rate of ZBTB7A wild-type patients was significantly higher than that of mutant type(P>0.05).<0.05).Conclusion The prognosis of patients with acute myeloid leukemia ASXL2 and ZBTB7A mutants is poor,and ASXL2 and ZBTB7A mutations may become molecular markers of poor prognosis.